



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C12N 15/12, C07K 14/47, C12N 15/79, 5/10</b>		A2	(11) International Publication Number: <b>WO 99/18203</b>
			(43) International Publication Date: 15 April 1999 (15.04.99)
(21) International Application Number: PCT/JP98/04475		(81) Designated States: AU, CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 5 October 1998 (05.10.98)			
(30) Priority Data: 9/276271 8 October 1997 (08.10.97) JP		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicants (for all designated States except US): SAGAMI CHEMICAL RESEARCH CENTER [JP/JP]; 4-1, Nishi-Ohnuma 4-chome, Sagamihara-shi, Kanagawa 229-0012 (JP). PROTEGENE INC. [JP/JP]; 2-20-3, Naka-cho, Meguro-ku, Tokyo 153-0065 (JP).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): KATO, Seishi [JP/JP]; 3-46-50, Wakamatsu, Sagamihara-shi, Kanagawa 229-0014 (JP). YAMAGUCHI, Tomoko [JP/JP]; 5-13-11, Takasago, Katsushika-ku, Tokyo 125-0054 (JP). SEKINE, Shingo [JP/JP]; Remonzu 101, 2-8-15, Atago, Ageo-shi, Saitama 362-0034 (JP). KOBAYASHI, Midori [JP/JP]; Royal Court 306, 3-2-3, Minami-Rinkan, Yamato-shi, Kanagawa 242-0006 (JP).			
(74) Agents: AOYAMA, Tamotsu et al.; Aoyama & Partners, IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi, Osaka 540-0001 (JP).			
(54) Title: HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND cDNAs ENCODING THESE PROTEINS			
(57) Abstract			
<p>The invention provides human proteins having transmembrane domains and cDNAs coding for these proteins as well as eukaryotic cells expressing said cDNAs. All of the proteins exist in the cell membrane, so that they are considered to be proteins controlling the proliferation and the differentiation of the cells. Accordingly, the proteins can be employed as pharmaceuticals such as carcinostatic agents relating to the control of the proliferation and the differentiation of the cells or as antigens for preparing antibodies against said proteins. The cDNAs can be utilized as probes for the gene diagnosis and gene sources for the gene therapy. Furthermore, the cDNAs can be utilized for large-scale expression of said proteins. Cells, wherein these membrane protein genes are introduced and membrane proteins are expressed in large amounts, can be utilized for detection of the corresponding ligands, screening of novel low-molecular pharmaceuticals, and so on.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Saxony
AZ	Azerbaijan	GB	United Kingdom	MU	Murico	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Malí	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	SL	Sierra Leone	UZ	Uzbekistan
CF	Central African Republic	JP	Japan				
CG	Congo (Brazzaville)	KZ	Kazakhstan	RO	Romania		
CR	Costa Rica	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	UK	United Kingdom	SL	Svalbard		